Confidential. Enter your access PIN / password.
🔐 Two-factor authentication. Enter the 6-digit code from your authenticator app.
The full investor presentation (June 2026) as a web page — mission, market, the adaptive cycle intelligence, traction, model, deep-tech moats, financials and the ask. Plus the rebuilt, validation-led financial model.
The intent of this rebuild is to turn the financial model from a directional forecast into a more credible, investor-ready planning tool.
The original model showed a promising business opportunity, but some assumptions were too aggressive, some outputs were hardcoded, and the scenarios did not fully flow from a single set of assumptions. That made it harder to test the business properly or defend the numbers under investor scrutiny.
The rebuilt model is designed to make the forecast more transparent, flexible, and evidence-led. It links the scenarios to clear assumptions, models growth through a monthly user funnel, separates B2C and B2B revenue logic, and distinguishes between assumptions supported by market references and assumptions that still need validation through real user data.
The purpose is not to make the numbers look bigger. It is to make them more believable.
A stronger financial model should help answer three investor questions clearly:
By making the Conservative case less aggressive and treating unproven assumptions as validation targets, the model becomes more useful as a decision-making tool. It can now support fundraising conversations, but also help the team identify what must be tested before scaling.
In short, the intent is to move the model from optimistic projection to defensible growth plan.
Formula-linked from the Assumptions tab. End-of-Year-3 outputs (a deliberately less aggressive Conservative case).
| Metric (End of Year 3) | Conservative | Realistic | Ambitious |
|---|---|---|---|
| Total paying users | ~5,870 | ~26,980 | ~93,870 |
| Total annual revenue | ~€316K | ~€1.30M | ~€3.4M+ |
| ARR at year end | ~€379K | ~€1.75M | ~€4.6M+ |
| Gross margin | ~83% | ~83% | ~84% |
| Financing modelled (seed + Series A) | €350K + €1.2M | €350K + €1.8M | €350K + €2.5–6M |
Figures from NUTRISYNC_financial_model_rebuilt.xlsx (Summary tab). Financing inflows are shown separately and are not treated as operating revenue.
| Assumption | Original model | Industry reality | Target to prove |
|---|---|---|---|
| Monthly free→paid conversion | 18% flat | 2–7% (top quartile) | ≥3% (conservative) |
| Monthly B2C churn (Y1) | 10% ("conservative") | 12–15% is the true downside; 66% of health apps abandoned in 90 days | Stress-test 12–15% |
| Wearable churn reduction | 50% | Structurally sound (hardware lock-in) | ≥20% reduction in 90-day cohorts |
| Waitlist → paid conversion | 25–42% | High-intent justified, but unproven at scale | Track real waitlist cohort |
| B2B contracts | Smooth scaling | Needs pipeline logic | 2 signed contracts / LOIs |
| AI cost per prompt | — | Can scale faster than revenue | < €0.005/prompt |
Full detail in the Validation Targets tab and the two review documents in the data room above.
Behind PIN + 2FA. Production access is logged per-file (Cloudflare Access / SSO + MFA).
Men run on a ~24-hour hormonal cycle; women on ~28 days across four phases. Generic nutrition ignores this — and women pay the cost.
Research & dosing skew male, raising risk for women.
Women's symptoms are under-recognized and under-served.
No guidance on food + training across cycle phases.
The "one-size-fits-all" diet ignores the 28-day cycle. NutriSync syncs food & training to each of the four phases.
Iron, warming foods, hydration. Gentle movement & rest.
Fresh foods, complex carbs, protein. Build intensity & strength.
Anti-inflammatory, fiber. Peak performance & HIIT.
Magnesium, complex carbs. Steady-state, wind down.
Aligned to UN SDG 3 (Good Health & Well-being) and SDG 5 (Gender Equality).
Personalized nutrition aligned with hormonal phases.
Symptom tracking & optimization engine.
For an underfunded healthcare segment.
Real-world cycle data + rising menstrual-health literacy.
NutriSync transforms menstrual cycle data into actionable, personalized guidance that adapts in real time to your biology and lifestyle. Personalized · science-backed · holistic · private by design.
A real-time 0–100 daily alignment score.
Improvement across cycles, not just today.
The scoring IP is implemented & unit-tested in packages/core/cas.mjs.
A fast-growing, specific segment — not the broad FemTech number. Cycle-synced nutrition is the wide-open wedge within it.
Spain's women's-health app + corporate wellness — everyone who could pay for cycle/hormonal wellbeing tech.
2M Spanish women already paying for digital health, plus B2B wellness buyers.
Spain share of the projected 400k users.
Sources: INE 2024 · Heraldo 2023 · Agencia SINC 2023 · European Psychiatry 2022.
| What it takes | Generic apps | Content apps | NutriSync |
|---|---|---|---|
| Science-backed cycle-sync framework | ◐ | ◐ | ● |
| Ethical data & privacy design | ◐ | ◐ | ● |
| Integrated cycle, nutrition & fitness plans | ◐ | ◐ | ● |
| AI personalization | — | ◐ | ● |
| Social & community features | ● | ◐ | ● |
| Direct-to-consumer | ● | ● | ● |
| Clinician-partnered distribution | — | — | ● |
| Institutional ATL outreach | — | — | ● |
| TTL data & insight loop | — | — | ● |
160 interviews · 96% report cycle impacts performance · 88% want a personalised solution.
€420+ from paid events · 32+ total paying attendees.
130 women waitlist · 30k organic views · university + corporate partnerships.
Backed by IE University, Loadmill, Women in Banking, Bolt.Earth, Viasat.
Subscription first, B2B as the multiplier, clinical partnerships as the moat.
Cycle-aware nutrition + fitness plans. Penetration pricing to maximise Y1 volume.
Launches month 13. AI personalised cycle plans + clinical consultation booking. ~160% more revenue per user.
Corporate wellness contracts. Avg 150 employees = €5,985/yr per contract; renews at €5.99.
Clinic referral fees, paid workshops/masterclasses, and founder brand partnerships.
Vercel pilot → App Store launch (M3) · CTO hired, first €4.99 subs · paid social from M4 (€3–5k/mo) · Apple HealthKit (M4–6) · AI personalisation engine (M6) · 2 clinical partners signed (B2B pilot) · GDPR health-data architecture.
Conversational AI companion (M13) · Premium €12.99 live · Oura Ring integration (M15) · predictive hormonal modelling (M20) · UK + Australia + Portugal · 10 B2B, 5 clinical partners · perimenopause tracking.
CGM integration · at-home hormone test-kit integration · menopause as dedicated product tier · population-health data layer · US launch, AI model matures · academic publication of clinical AI findings.
4K followers today → 50K+ by Y3. Zero marginal CAC.
€3–5k/mo IG & TikTok · CAC €6–8 (~50% below industry) · 375–625 new users/mo.
1 × 150-employee contract = 150 users instantly · 50 patient conversions/clinic/mo · 5 contracts = 750 B2B users Y1.
Already revenue-generating · 40–60% convert to subscribers · 2 events = €500–1k/event.
ARR €1.04M annualised.
Deep-tech Y2+ impact.
Breakeven around quarter 11.
Note: the rebuilt financial model (above) deliberately makes the Conservative case less aggressive than these deck figures — ~5.9K paying users / ~€316K revenue by Y3 — and treats unproven assumptions as validation targets. Use the rebuilt model for diligence; the deck figures reflect the prior projection.
Now → M6.
M13 (Premium).
Mid-stage.
Series A, Y3.
3+ months of tracking creates a unique hormonal data signature. Competitors would need ~5 years to build it.
Clinical partnerships take 12–18 months; a generic app can't replicate branded clinical content in 6.
Founder social channels = 50K+ combined audience, zero-marginal-CAC advantage in the exact target demographic.
Access 100M+ existing devices, no hardware to build.
M4. HR, HRV, sleep, activity, skin temp, blood oxygen. 60% of target own one; API free, 4–6 wks dev.
M4. Spain & Australia (Android 70%+), shared codebase, low marginal cost.
Y3. Skin-temp trend, HRV readiness, sleep — automatic cycle prediction.
Y3. Blood glucose across the cycle; most complete hormonal-nutrition picture.
7% CAGR. Same infrastructure, different life stage, higher ARPU.
Proven demand, almost no tech supply.
Mostly symptom trackers — no integrated nutrition layer.
Strategy consulting & research
UX/UI & product development
Branding & marketing strategy
Technology & Digital Transformation — CTO of CHUBB. Supports digital infrastructure, scalability and AI-driven UX.
AI & Growth Strategy — CRO of Global Sales at Loadmill. Advises on scaling growth.
Strategy & Brand Innovation — Former Global Innovation Lead at ING.
Clinical Nutrition — ensures the nutritional approach is science-based.
Finance & Governance — Senior Credit Analyst at AXA. Financial oversight & funding strategy.
NutriSync provides wellness & educational guidance, not medical advice. Confidential — for invited investors, advisors, and team only.
investor.html), rendered as-is.Internal — Admin/MIS & project documentation. Enter your access PIN.
🔐 Two-factor authentication. Enter the 6-digit code from your authenticator app.
| Year | Users | Revenue | Cost | Profit |
|---|